drugset / Trial / NCT02659800
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Phase 1
Terminated
12 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collabNeoImmuneTech · collab
RandomizedParallel-groupDouble-blindSupportive care
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and select optimal biological doses (OBD) of the study drug NT-I7 in High Grade Glioma patients with severe lymphopenia, as well as to test the effect of NT-I7 on the CD4 counts of patients in comparison to control participants. This study has both a Phase I and Pilot component.
Timeline
- Start
- 2018-10-30
- Primary completion
- 2022-03-30
- Completion
- 2023-10-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NT-I7 | Protein / enzyme biologic | 60 ug/kg | Intramuscular |